{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-049136","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.521272+00:00","generated_at":"2026-06-05T08:05:48.224295+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Madrigal names Mardi Dier as CFO; Alex Howarth transitions to advisor; GC Brian Lynch to depart by May 31","bullets":["Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.","Dier receives $550K base salary, 45% target bonus, and $6.7M equity grant (RSUs, options, PSUs) under 2023 Inducement Plan.","Outgoing CFO Alex Howarth remains Senior Advisor to May 31; separation includes 12-month salary, target bonus, equity acceleration, health benefits.","SVP & General Counsel Brian Lynch to depart by May 31; similar separation terms: 12-month salary, target bonus, equity acceleration, health benefits.","No disagreements with accounting policies or internal controls related to either departure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-049136","json":"https://secwatch.observer/filing/0001193125-24-049136.json","markdown":"https://secwatch.observer/filing/0001193125-24-049136.md","text":"https://secwatch.observer/filing/0001193125-24-049136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/0001193125-24-049136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/d757603d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:05:48.224295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15bfced94d","claim":"Mardi C. Dier was appointed as Senior Vice President and Chief Financial Officer at MADRIGAL PHARMACEUTICALS, INC..","evidence_excerpt":"On February 28, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) announced the appointment of Mardi C. Dier as Senior Vice President and Chief Financial Officer of the Company, effective March 11, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524049136/0001193125-24-049136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}